The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy.
作者信息
Lotze Michael T
出版信息
Curr Opin Investig Drugs. 2003 Jun;4(6):649-51.
PMID:12901221
Abstract
摘要
相似文献
1
The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy.
Curr Opin Investig Drugs. 2003 Jun;4(6):649-51.
2
Molecular targets and cancer therapeutics.
Drug Discov Today. 2004 Dec 15;9(24):1042-4. doi: 10.1016/S1359-6446(04)03287-8.
3
Cancer nanotechnology: small, but heading for the big time.癌症纳米技术：虽小，但正迈向辉煌时代。
Nat Rev Drug Discov. 2007 Mar;6(3):174-5. doi: 10.1038/nrd2285.
4
The impact of systems approaches on biological problems in drug discovery.系统方法对药物发现中生物学问题的影响。
Nat Biotechnol. 2004 Oct;22(10):1215-7. doi: 10.1038/nbt1004-1215.
5
Seeing is believing--visualizing drug delivery in vitro and in vivo.眼见为实——体外和体内药物递送的可视化
Adv Drug Deliv Rev. 2005 Jun 15;57(8):1085-6. doi: 10.1016/j.addr.2005.01.019.
6
INGN-241. Introgen.INGN - 241。英特洛根公司。
Curr Opin Investig Drugs. 2002 Dec;3(12):1773-7.
7
Chemical biology and drug design: three-dimensional, dynamic, and mechanistic nature of two multidisciplinary fields.化学生物学与药物设计：两个多学科领域的三维、动态及机制特性。
Chem Biol Drug Des. 2006 Mar;67(3):196-200. doi: 10.1111/j.1747-0285.2006.00371.x.
8
Value of novelty?新奇性的价值？
Nat Rev Drug Discov. 2002 Aug;1(8):571-2. doi: 10.1038/nrd884.
9
Advances in molecular targets and cancer therapeutics.
Drug Discov Today. 2004 Mar 1;9(5):207-9. doi: 10.1016/S1359-6446(03)03001-0.
10
Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy.肿瘤缺血的选择性诱导：用于癌症治疗的血管靶向药物的研发
Curr Opin Investig Drugs. 2002 Sep;3(9):1381-4.
引用本文的文献
1
Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells.识别肿瘤生物标志物和替代指标（癌症生物计量学）：与免疫疗法和免疫细胞的相关性
Cancer Immunol Immunother. 2004 Mar;53(3):256-61. doi: 10.1007/s00262-003-0487-3. Epub 2004 Jan 21.
Zotero 插件